RXST
Rxsight Inc
NASDAQ: RXST · HEALTHCARE · MEDICAL DEVICES
$6.81
-5.02% today
Updated 2026-04-29
Market cap
$295.88M
P/E ratio
—
P/S ratio
2.20x
EPS (TTM)
$-0.95
Dividend yield
—
52W range
$6 – $17
Volume
0.7M
Rxsight Inc (RXST) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.24M | $14.68M | $22.59M | $49.01M | $89.08M | $139.93M | $134.48M |
| Revenue growth (YoY) | — | +555.0% | +53.9% | +116.9% | +81.8% | +57.1% | -3.9% |
| Cost of revenue | $4.06M | $12.97M | $18.08M | $27.68M | $35.31M | $40.98M | $31.47M |
| Gross profit | $-1.82M | $1.71M | $4.52M | $21.33M | $53.77M | $98.94M | $103.01M |
| Gross margin | -81.2% | 11.6% | 20.0% | 43.5% | 60.4% | 70.7% | 76.6% |
| R&D | $29.57M | $21.93M | $24.50M | $25.98M | $29.05M | $34.37M | $38.55M |
| SG&A | $15.20M | $15.18M | $32.80M | $58.66M | $74.80M | $101.43M | $112.65M |
| Operating income | $-46.07M | $-35.41M | $-52.79M | $-63.32M | $-50.09M | $-36.86M | $-48.19M |
| Operating margin | -2055.8% | -241.2% | -233.6% | -129.2% | -56.2% | -26.3% | -35.8% |
| EBITDA | $130.20M | $32.15M | $-41.01M | $-57.78M | $-41.04M | $-23.76M | $-39.62M |
| EBITDA margin | 5809.9% | 219.1% | -181.5% | -117.9% | -46.1% | -17.0% | -29.5% |
| EBIT | $126.27M | $28.14M | $-45.00M | $-61.80M | $-45.28M | $-27.38M | $-38.84M |
| Interest expense | $26000.00 | $510000.00 | $3.68M | $4.95M | $3.31M | $21000.00 | $40000.00 |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $126.22M | $27.57M | $-48.69M | $-66.76M | $-48.61M | $-27.45M | $-38.94M |
| Net income growth (YoY) | — | -78.2% | -276.6% | -37.1% | +27.2% | +43.5% | -41.8% |
| Profit margin | 5632.3% | 187.9% | -215.5% | -136.2% | -54.6% | -19.6% | -29.0% |